About The Study: The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes across the full spectrum of kidney function and albuminuria among patients with type 2 diabetes, chronic kidney disease, or heart failure.
Corresponding Authors: To contact the corresponding authors, email Brendon L. Neuen, PhD ( bneuen@georgeinstitute.org.au ) and Hiddo J. L. Heerspink, PhD ( h.j.lambers.heerspink@umcg.nl ).
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.20834)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the American Society of Nephrology Kidney Week 2025 meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.20834?guestAccessKey=5cb973ba-2a15-4b6d-8e39-05dff6b0a313&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110725
JAMA